



Current Practices in Estimation and Prediction

OHDSI Community Call
April 22, 2025 • 11 am ET



Upcoming Community Calls

| Date | Topic |
|---------|---|
| Apr. 22 | Current Practices in Estimation and Prediction |
| Apr. 29 | DevCon 2025 Review |
| May 6 | Evidence Synthesis |
| May 13 | Maternal Health Fellowship Review |
| May 20 | Guideline-Driven Evidence Study Review |
| May 27 | Collaborator Showcase Brainstorm (Deadline is July 1) |



Three Stages of The Journey

Where Have We Been?

Where Are We Now?

Where Are We Going?





OHDSI Shoutouts!



Congratulations to the team of **Daniel Kapitan, Femke Heddema, André Dekker, Melle Sieswerda, Bart-Jan Verhoeff, and Matt Berg** on the publication of **Data Interoperability in Context: The Importance of Open-Source Implementations When Choosing Open Standards in the** *Journal of Medical Internet Research*.

JOURNAL OF MEDICAL INTERNET RESEARCH

Kapitan et al

Viewpoint

Data Interoperability in Context: The Importance of Open-Source Implementations When Choosing Open Standards

Daniel Kapitan^{1,2,3}, DPhil; Femke Heddema², MSc; André Dekker⁴, Prof Dr; Melle Sieswerda⁵, MD, MSc; Bart-Jan Verhoeff⁶, MD; Matt Berg⁷, BA, MBA

¹Eindhoven AI Systems Institute (EASIS), Eindhoven University of Technology, Eindhoven, The Netherlands

²PharmAccess Foundation, Amsterdam, The Netherlands

³Dutch Hospital Data, Utrecht, The Netherlands

⁴MAASTRO Clinic, Maastricht University Medical Centre, Maastricht University, Maastricht, The Netherlands

⁵Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands

⁶Expertisecentrum Zorgalgoritmen, Utrecht, The Netherlands

⁷Ona, Burlington, VT, United States

Corresponding Author:

Daniel Kapitan, DPhil

Eindhoven AI Systems Institute (EASIS)

Eindhoven University of Technology

PO Box 513

Eindhoven, 5600 MB

The Netherlands

Phone: 31 624097295

Email: daniel@kapitan.net

Abstract

Following the proposal by Tsafnat et al (2024) to converge on three open health data standards, this viewpoint offers a critical reflection on their proposed alignment of openEHR, Fast Health Interoperability Resources (FHIR), and Observational Medical Outcomes Partnership (OMOP) as default data standards for clinical care and administration, data exchange, and longitudinal analysis, respectively. We argue that open standards are a necessary but not sufficient condition to achieve health data interoperability. The ecosystem of open-source software needs to be considered when choosing an appropriate standard for a given context. We discuss two specific contexts, namely standardization of (1) health data for federated learning, and (2) health data sharing in low- and middle-income countries. Specific design principles, practical considerations, and implementation choices for these two contexts are described, based on ongoing work in both areas. In the case of federated learning, we observe convergence toward OMOP and FHIR, where the two standards can effectively be used side-by-side given the availability of mediators between the two. In the case of health information exchanges in low and middle-income countries, we see a strong convergence toward FHIR as the primary standard. We propose practical guidelines for context-specific adaptation of open health data standards.



OHDSI Shoutouts!



Congratulations to the team of **Young Hwa Lee, Young June Choe, Yoon Sun Yoon, Ji Young Park, Yun-Kyung Kim, Hyung Joon Joo, Sujin Choi, Hyun Jung Kim and Lorenzo Bertizzolo** on the publication of **Predicting ICU Admission Risk in Children with Respiratory Syncytial Virus in *Infectious Diseases and Therapy***.

Infect Dis Ther
<https://doi.org/10.1007/s40121-025-01155-w>

ORIGINAL RESEARCH

Predicting ICU Admission Risk in Children with Respiratory Syncytial Virus

Young Hwa Lee · Young June Choe[✉] · Yoon Sun Yoon · Ji Young Park · Yun-Kyung Kim · Hyung Joon Joo · Sujin Choi · Hyun Jung Kim · Lorenzo Bertizzolo

Received: February 26, 2025 / Accepted: April 2, 2025
© The Author(s) 2025

ABSTRACT

Introduction: Respiratory syncytial virus (RSV) is a common infection in young children and a frequent cause of hospitalization. In some cases, RSV can lead to severe lower respiratory tract illness requiring admission to the intensive care unit (ICU). Here, we explore risk factors for RSV-related ICU admission in children.

Methods: We conducted a retrospective study using Electronic Medical Record (EMR) data

transformed into the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) from three tertiary care centers in Korea between 2008 and 2022. We identified 1529 children hospitalized with RSV according to the CDM and examined risk factors for ICU admission in this population.

Results: Of 33,674 children aged 0–9 years who tested for RSV, 1529 (4.5%) were positive. The highest proportion of RSV-positive children were less than 10 months old. The ICU admission rate among RSV-positive children was 1.8% (29/1529), and the highest ICU admission rate occurred in children aged 0–5 months (4.4%). In a multivariable logistic regression model, we found that the

Prior Presentation: Part of this study was presented at the RSVVW'24 Conference, 13th–16th February 2024, in Mumbai, India.



OHDSI Shoutouts!



Congratulations to the team of **Jenna Reps, Peter Rijnbeek and Patrick Ryan** on the publication of **Can we develop real-world prognostic models using observational healthcare data? Large-scale experiment to investigate model sensitivity to database and phenotypes** in *Diagnostic and Prognostic Research*.

Reps et al.
Diagnostic and Prognostic Research (2025) 9:10
<https://doi.org/10.1186/s41512-025-00191-x>

Diagnostic and
Prognostic Research

RESEARCH

Open Access



Can we develop real-world prognostic models using observational healthcare data? Large-scale experiment to investigate model sensitivity to database and phenotypes

Jenna M. Reps^{1,2*}, Peter R. Rijnbeek² and Patrick B. Ryan¹

Abstract

Background Large observational healthcare databases are frequently used to develop models to be implemented in real-world clinical practice populations. For example, these databases were used to develop COVID severity models that guided interventions such as who to prioritize vaccinating during the pandemic. However, the clinical setting and observational databases often differ in the types of patients (case mix), and it is a nontrivial process to identify patients with medical conditions (phenotyping) in these databases. In this study, we investigate how sensitive a model's performance is to the choice of development database, population, and outcome phenotype.

Methods We developed > 450 different logistic regression models for nine prediction tasks across seven databases with a range of suitable population and outcome phenotypes. Performance stability within tasks was calculated by applying each model to data created by permuting the database, population, or outcome phenotype. We investigate performance (AUROC, scaled Brier, and calibration-in-the-large) stability and individual risk estimate stability.

Results In general, changing the outcome definitions or population phenotype made little impact on the model validation discrimination. However, validation discrimination was unstable when the database changed. Calibration and Brier performance were unstable when the population, outcome definition, or database changed. This may be problematic if a model developed using observational data is implemented in a real-world setting.

Conclusions These results highlight the importance of validating a model developed using observational data in the clinical setting prior to using it for decision-making. Calibration and Brier score should be evaluated to prevent miscalibrated risk estimates being used to aid clinical decisions.



Three Stages of The Journey

Where Have We Been?

Where Are We Now?

Where Are We Going?





Upcoming Workgroup Calls



| Date | Time (ET) | Meeting |
|-----------|-----------|--------------------------------------|
| Tuesday | 12 pm | ATLAS |
| Wednesday | 9 am | Oncology Outreach/Research Subgroup |
| Wednesday | 12 pm | Latin America |
| Thursday | 9:30 am | Network Data Quality |
| Thursday | 7 pm | Dentistry |
| Friday | 9 am | Phenotype Development and Evaluation |
| Monday | 9 am | Vaccine Vocabulary |
| Monday | 10 am | Africa Chapter |
| Monday | 10 am | The Getting Started Subgroup |
| Monday | 11 am | Book of OHDSI |
| Tuesday | 9:30 am | CDM Survey Subgroup |



DevCon 2025: April 25

Agenda

9:00 – 9:15am ET • Welcome & Introduction

- Paul Nagy, Johns Hopkins University

9:15 – 11:30am ET • OHDSI Projects Lightning Talks

- Stabilizing Gaia Core – Robert Miller, Miller Data Solutions
- CustomVocabularyBuilder – Jared Houghtaling, Tufts University
- CohortConstructor – Núria Mercadé-Besora, University of Oxford
- Updates on Strategus – Anthony Sena, Johnson & Johnson
- Experiences with SQLMesh/CICD integration with Databricks – Vishnu Chandrabalan, Lancashire Teaching Hospitals NHS Foundation Trust
- Updates from the Technical Advisory Board – Frank Defalco, Johnson & Johnson

11:30 – 12:30pm ET • Developer dialogue: Dev ops, DBT and, of course, LLMs

Moderator: Katy Sadowski, Boehringer Ingelheim

- Eduard Korchmar, EPAM Systems
- Egill Fríðgeirsson, Erasmus MC
- Martin Lavalley, Boehringer Ingelheim
- Lawrence Adams, Artificial Intelligence Centre for Value Based Healthcare

12:30 – 1:00pm ET • Break

1:00 – 2:00pm ET • Sustainable Open-Source Ecosystems Panel

Moderator: Paul Nagy, Sean O'Reilly

- Data4Life – Peter Hoffmann
- The Hyve – Jan Blom/Wouter Franke
- Cognome – James Green



ohdsi.org/DevCon2025



Columbia Summer School on OHDSI

Registration is open for the first ever Columbia Summer School on OHDSI, held July 14-18, 2025, at the Columbia University Department of Biomedical Informatics in New York City.

The Columbia Summer School in Observational Health Data Science and Informatics, Artificial Intelligence, and Real World Evidence (RWE) offers health professionals, researchers and industry practitioners the opportunity to gain familiarity and hands-on experience with real world data and generating real world evidence. Participants will learn about the different types of healthcare data captured during routine clinical care, including electronic health records and administrative records, and how these data can be standardized to the OMOP Common Data Model to enable distributed data network research.



Meet Our Faculty



George Hripcsak, MD MS
Vivian Beaumont Allen
Professor of Biomedical
Informatics



Patrick Ryan, PhD
Adjunct Assistant
Professor of Biomedical
Informatics



Anna Ostropolets, MD PhD
Adjunct Assistant
Professor of Biomedical
Informatics



Karthik Natarajan, PhD
Assistant Professor of
Biomedical Informatics



Save The Date!

The submission deadline for the
2025 Global Symposium
Collaborator Showcase is **July 1**.

The showcase will be accepting both posters and software demos, as well as interest in hosting lightning talks. More information on the symposium, including abstract submission and registration links, will be available soon.



#OHDSISocialShowcase This Week

Monday

PHederation - the federated network of Pulmonary Hypertension registries

(Eva-Maria Didden, Valerie van Baalen, Michel van Speybroeck, Monika Brand)



PRESENTER: Michael Briganti
CO-AUTHORS: Eva-Maria Didden, Valerie van Baalen, Michel van Speybroeck, Monika Brand

INTRO

- Pulmonary Arterial Hypertension (PAH) is a rare subgroup of Pulmonary Hypertension (PH).
- Real-world evidence (RWE) generation in rare diseases is often restricted due to small patient numbers, geographic distribution, and limited data access.
- Federated Data Networks (FDNs) can bring together multiple fit-for-purpose data sources.
- PHederation is a public-private partnership connecting disease-specific clinical data sources for enhanced, transparent, and reproducible research in PH (Ref.1).

METHODS

PHederation data network

- Each database custodian is in control of patient-level data and responsible for privacy, ethics and legal compliance.
- The IT infrastructure consists of a central hub and local software instances, for controlled exchange of queries and result (Fig.1).




Figure 1. PHederation Portal and mechanisms for collaboration.

Data harmonization

All data were originally mapped to OMOP CDM v.5.3.1 (Ref. 2-3) and undergo refreshes to OMOP CDM v.5.4.1.

Study conduct

- Select databases from Data Catalogue (Table 1) and perform fit for purpose evaluations.
- Create study team to develop protocol and analysis plan.
- Translate analysis plan into executable queries.
- Distribute queries, execute analysis, share aggregate results, and potentially conduct meta-analysis.
- Interpret results, write study report, publish.

PHederation

sets a blueprint

for future disease-specific federated data networks.

Visit us at PHederation.org!



RESULTS

| Title of the database | Description | Observation period | Number of PH and PAH patients | Regions | Source data format/collection |
|---------------------------------------|--|--------------------|-------------------------------|----------------------------|-------------------------------|
| Canadian PH Registry (CPRH) | Prospective PH patient registry | 2017 - ongoing | PH - 1 195 PAH - 1 076 | Canada | PAHTool |
| EXPOSURE (EUPAS1908) | Registry of PAH patients newly treated with either Uptravi or another PAH-specific therapy | 2017 - ongoing | PAH - 2 354 | Europe, Canada | CDISC SDTM |
| OPUS (NCT01268943) | Opsumit drug registry | 2014 - 2018 | PH - 2 674 PAH - 2 208 | USA | CDISC SDTM |
| ORPHUS | Opsumit user medical chart review to supplement OPUS | 2013 - 2017 | PH - 1 031 PAH - 2 410 | USA | CDISC SDTM |
| Porto center of Portuguese PH network | Portuguese PH registry | 2001 - ongoing | PH - 578 PAH - 216 | Portugal - Northern Region | PAHTool |
| SPHERE (NCT01274002) | Sildenafil drug registry | 2016 - 2020 | PH - 829 PAH - 799 | USA | Registry-specific |
| Stanford clinical PH database | PH Registry | 2004 - ongoing | PH - 1 189 PAH - 987 | USA - Western Region | Registry-specific |

Table 1. PHederation Data Catalogue.




Figure 2. PHederation Dashboard: Patient demographics and disease characteristics at enrolment, and geographic coverage.

CONCLUSION & OUTLOOK

PHederation established a network of databases

- of diverse purpose and origin
- with the goal of advancing scientific knowledge in PH through distributed data sources and analytics, harmonization, and automation.

First PHederation network study (ongoing):

- Objective: Drug utilization assessment of ERAs and PDE-5 inhibitors in newly-diagnosed PAH patients.
- Goal: To complement DARWIN-EU's EUPAS106052 (Ref.4) with evidence from a disease-specific FDN.

REFERENCES:

- Transparency and reproducibility through disease-specific FDNs: <https://pubmed.ncbi.nlm.nih.gov/38955812/>
- Standardizing PH registry data to the OMOP Common Data Model: <https://pubmed.ncbi.nlm.nih.gov/34727871/>
- Handbook for PH registries to OMOP CDM conversion: <https://github.com/OHDSI/ETL-PulmonaryHypertensionRegistries>
- EUPAS106052: <https://catalogues.ema.europa.eu/node/3797/administrative-details>



#OHDSISocialShowcase This Week

Tuesday

Gap Analysis of Static Automated Perimetry Concept Representation in OMOP CDM

(**Shahin Hallaj**, William Halfpenny, Niloofar Radgoudarzi, Michael V. Boland, Swarup S. Swaminathan, Sophia Y. Wang⁵, Benjamin Y. Xu, Dilru C. Amarasekera, Brian Stagg, Michelle Hribar, Kaveri A. Thakoor, Kerry E. Goetz, Jonathan S. Myers, Aaron Y. Lee, Mark A. Christopher, Linda M. Zangwill, Robert N. Weinreb, Sally L. Baxter)



Advancing Towards Representation of Static Perimetry Data in the OMOP CDM: A Collaborative Approach to Overcoming

Shahin Hallaj^{1,2}, Swarup S. Swaminathan³, Sophia Y. Wang⁴, Benjamin Y. Xu⁵, Dilru Amarasekera⁶, Michael V. Boland⁷, Brian Stagg^{8,9}, Michelle Hribar^{10,11,12}, Kaveri A. Thakoor^{13,14}, Kerry E. Goetz¹⁵, Jonathan S. Myers⁶, Aaron Y. Lee¹⁶, Mark A. Christopher¹, Linda M. Zangwill¹, Robert N. Weinreb¹, Sally L. Baxter^{1,2}

1. Division of Ophthalmology Informatics and Data Science, Hamilton Glaucoma Center, Shiley Eye Institute, University of California, San Diego, 2. Division of Biomedical Informatics, Department of Medicine, University of California San Diego, 3. Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, 4. Byers Eye Institute, Department of Ophthalmology, Stanford University, 5. Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine at the University of Southern California, 6. Glaucoma Service, Wills Eye Hospital, Philadelphia, 7. Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, 8. Department of Ophthalmology and Visual Sciences, John Moran Eye Center, University of Utah, Salt Lake City, 9. Department of Population Health Sciences, University of Utah, 10. Office of Data Science and Health Informatics, National Eye Institute, National Institutes of Health, 11. Department of Ophthalmology, Casey Eye Institute, 12. Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, 13. Department of Biomedical Engineering, Columbia University, 14. Department of Ophthalmology, Columbia University Irving Medical Center, 15. Department of Ophthalmology, School of Medicine, University of Washington

Background

- ✓ The endpoint of clinical glaucoma care is to preserve vision and minimize visual field loss.
- ✓ This data is often unavailable in "big data", e.g., All of Us, Institutional EHR data warehouses, and Epic Cosmos.
- ✓ Enhancing data harmonization and interoperability will facilitate clinical research and, ultimately, patient management.

Methods



Figure 1. Workflow and reviewed modalities of the study.
Contact: shahin@health.ucsd.edu

Results

- Limited adoption of ophthalmic visual field (OPV) DICOM standard across institutions and vendors

Table 1. Variations in data export methods and resulting files as one of the main identified barriers.

| Data Source | Extraction Method | File Formats |
|-----------------------------------|---|--|
| Humphrey Field Analyzer | Advanced export tool or direct extraction | Proprietary DICOM, PDF encapsulated DICOM, Raw DICOM, XML, OPV DICOM |
| Haag-Streit Octopus 900 Perimeter | Research export tool or DICOM export tool requires additional license | CSV, ESK, OPV DICOM, Perl Data |

- Limited granted access to advanced data export tools
 - Vendors charge for granting access to data export modules

- Non-comparable Data Elements between Perimeters from Different Vendors

- Because of differences in:
 - Maximum stimulus luminance used (OPS: 4,000 asb, HFA: 10,000 asb)
 - This may differ in different models/versions of the same device
 - Device-specific normative databases
 - Mean defect vs. mean deviation: HFA algorithms assign more weight to the central points, whereas OPS weights all the points equally
 - Test location coordinates

- Limited Concept Coverage Within The OMOP CDM

- No representation of point-level and cluster-level data elements
- No representation of trend analysis
- Notably, OMOP CDM included codes describing phenotypes. (e.g., paracentral scotoma)



Figure 2. Mapping of the extracted data elements to OMOP concepts.

Conclusions

- Harmonization and representation of the perimetry data elements can enable the addition of these data elements in big data resources, enabling powerful modeling, discovery, and innovation.
- Limited adaptation of OPV DICOM standards by the vendors and institutions hinder application of the existing powerful DICOM-based developed tools in ophthalmology.
- Addressing these challenges is crucial for achieving data harmonization, promoting interoperability, implementing artificial intelligence, and empowering future multicenter clinical research.



Scan to see the results of gap analysis.



Financial support: Research to prevent blindness, National Institutes of Health grants: OT200032644, DP5OD029610, P30EY022589.



@OHDSI

www.ohdsi.org

#JoinTheJourney



ohdsi



#OHDSISocialShowcase This Week

Wednesday

Enhancing Cardiovascular Adverse Event Detection in ICI-Treated Cancer Patients: Lessons Learned from Natural Language Processing Integration with OMOP CDM

(Clara L. Oeste, Danielle Delombaerde, Iege Bassez, Annelies Verbiest, Philip Debruyne, Christof Vulsteke, Dries Hens)

1056P Real-world usage and adverse events (AE) of immune checkpoint inhibitors (ICI): A large-scale, automated, GDPR-compliant analysis of hospital records

Annelies Verbiest¹, Philip Debruyne², Iege Bassez², Danielle Delombaerde^{4,5}, Laura Tack³, Clara L. Oeste¹, Laura Deckx¹, Lieselot Croes¹, Dries Hens¹, Vincent Geldhof¹, Hans Prenen^{1,5}, Christof Vulsteke^{1,5}

¹Department of Oncology, Multidisciplinary Oncological Center Antwerp, Antwerp University Hospital, Belgium; ²Department of Medical Oncology, General Hospital AZ Groeninge, Kortrijk, Belgium; ³LYNCare, Leuven, Belgium; ⁴Department of Oncology, General Hospital AZ Maria Middelaere, Ghent, Belgium; ⁵Center for Oncological Research (CORE), University of Antwerp, Antwerp, Belgium




BACKGROUND AND AIMS

- Immune checkpoint inhibitors (ICI) form a backbone of curative and non-curative treatment across cancer types, yielding survival benefits as well as costs and AEs.
- The interplay between these is challenging to estimate from trial data and classical real-world data (claims, registries) because of the heterogeneity of patient populations and outcomes.
- The Observational Medical Outcomes Partnership Common Data Model (OMOP CDM) is designed for analysis of cross-domain observational health data.

METHODS

- Retrospective multicenter study
- Processed anonymized electronic health records (EHR) using natural language processing (NLP) and machine learning.
- The pipeline mapped 597 variables to SNOMED-CT
- Detected adverse events (AE) on ICI treatment and comorbidities before ICI
- The resulting OMOP CDM databases were validated per hospital, ensuring patient privacy.



RESULTS AND CONCLUSIONS




Table 1. Patient demographics. The sex, age, and performance status are shown for the total population.

| Patients, n (%) | |
|--------------------|----------|
| Total | 1574 |
| Female | 537 (34) |
| Age (median) | 67y |
| Performance status | |
| 0 | 255 (26) |
| 1 | 484 (30) |
| 2-4 | 229 (24) |
| Unknown | 606 |

Contact: Dr. Annelies Verbiest, annelies.verbiest@uza.be
BioRxiv: A.V. declares speaker fees (Pharos, Bristol) and advisory board and congress fees (Ipsum), all paid directly to UZA. Sponsor wants reference to LyncCare Health Informatics IT development, no customer contacts.

Figure 1. Events detected before and during ICI treatment. Event distribution is shown as detected before ICI treatment (i.e., comorbidities, in orange) or on ICI treatment (i.e., adverse events, AEs, in blue) for total and specific events. The time of onset for specific AEs is shown in violin plots on the right (from first ICI administration to 3 months after last ICI administration). Red dots and numbers represent patients with administration of non-corticosteroid immunosuppressants (ncIs) and its timing (if within the first 12 months).




Table 2. ICI treatment characteristics per primary cancer type. The number of patients, ICI administrations, and median (95% CI) real-world time on treatment (rwToT) are shown per primary cancer type.

| Primary cancer | Patients, n (%) | ICI administrations, n (%) | rwToT, median (95% CI) in days* |
|--|-----------------|----------------------------|---------------------------------|
| TOTAL | 1574 | 18584 | - |
| Lung | 730 (46) | 8145 (44) | - |
| NSCLC | 607 (39) | 7231 (39) | 147 (132 - 175) |
| SCLC | 72 (5) | 485 (3) | 126 (88 - 147) |
| Unspecified | 51 (3) | 429 (2) | 106 (73 - 181) |
| Melanoma | 229 (15) | 3580 (19) | 252 (168 - 336) |
| Head and neck | 139 (9) | 1481 (8) | 84 (70 - 124) |
| Urothelial | 137 (9) | 1451 (8) | 105 (63 - 147) |
| Renal cell | 133 (9) | 2169 (12) | 203 (160 - 336) |
| Mesothelioma | 59 (4) | 684 (4) | 126 (105 - 210) |
| Hepatocellular | 34 (2) | 308 (2) | 85 (42 - 560) |
| Breast | 32 (2) | 326 (2) | 168 (114 - not reached) |
| Esophageal | 26 (2) | 206 (1) | 91 (67 - 141) |
| Endometrial | 16 (1) | 123 (1) | 85.5 (42 - not reached) |
| Colorectal | 13 (1) | 160 (1) | 971 (70 - not reached) |
| OTHER (cervical, gastric, biliary, cutaneous squamous cell carcinoma, basal cell carcinoma, Merkel cell carcinoma, Hodgkin lymphoma) | 26 (2) | 427 (2) | - |

CONCLUSIONS:

- We were able to build granular real-world data warehouses across hospitals on >1500 ICI patients.
- Lung carcinoma constituted 46% of ICI-indications.
- Among AEs that can be ICI-related, diabetes mellitus was the main AE detected before start of ICI (21% patients)
- AEs detected on ICI-treatment varied.



#OHDSISocialShowcase This Week

Thursday

Electrocardiogram-Based Identification of Acute Heart Failure in Chronic Heart Failure: A MIMIC-IV and OMOP-CDM Standardized Approach

(Seung Wook Lee)

Electrocardiogram-Based Identification of Acute Heart Failure in Chronic Heart Failure: A MIMIC-IV and OMOP-CDM Standardized Approach

PRESENTER: **Seung Wook Lee**


INTRO:

- Acute heart failure (AHF) is a rapid worsening of heart failure due to fluid overload, leading to symptoms like shortness of breath and swelling. This is especially concerning for chronic heart failure (CHF) patients, who face higher risks of hospitalization and mortality.
- Diagnosing AHF typically involves imaging and lab tests, but these require medical attention or specialized equipment.
- This study explores using ECG data as a non-invasive tool to identify AHF in CHF patients, leveraging data from the MIMIC-IV database standardized to OMOP-CDM guidelines.

METHODS

- Dataset: MIMIC-IV and MIMIC-IV-ECG from PhysioNet, standardized to OMOP-CDM. (Observation period: 2008-2019)
- Inclusion Criteria: those with diagnosis of CHF, those with ECG measured within 12 hours of ED admission, those with concurrent diagnosis of AHF during observation period
- Study Population: Final cohort included 6,988 CHF patients with 40,239 ECGs
- Baseline ECG and demographic features were identified. ECG differences were computed for 33,251 studies after excluding 6,988 baseline ECGs.
- Final Analysis Group: 21,315 non-AHF ECGs, 11,936 AHF ECGs.
- Analysis: XGBoost model developed using age, gender, and ECG-derived features. Performance measured using AUROC and AUPRC.

ECG data may assist in identifying acute heart failure in chronic heart failure patients, offering a potential tool to support diagnosis.



Results

- Analyzed 6,988 chronic heart failure (CHF) patients, yielding 11,936 ECGs associated with AHF events and 21,315 without AHF.
- Using an XGBoost model, we achieved an AUROC of 0.68 and an AUPRC of 0.54, with a recall of 0.80 and precision of 0.45.
- Key predictors of AHF included QRS axis, RR interval, P wave axis, and T wave axis, reflecting underlying cardiac stress and electrical disturbances commonly seen in AHF.

Conclusion

- ECG data combined with machine learning may assist in identifying acute heart failure (AHF) in chronic heart failure (CHF) patients.
- The model's moderate AUROC and AUPRC suggest it should be used alongside other diagnostic tools.
- High recall indicates its potential for identifying patients at risk of AHF.
- Further validation using external datasets is needed to confirm robustness and generalizability.

Limitations

- The model was trained on a single cohort (MIMIC-IV database), limiting generalizability.
- External validation in diverse populations is necessary.
- The study used only ECG-derived features and demographic data, excluding other clinical information that may improve accuracy.
- Moderate AUROC (0.68) and low precision indicate this method should supplement, not replace, other diagnostic approaches in clinical practice.



LinkedIn Profile

Abstract (pdf)

Seung Wook Lee,
Department of Medicine,
MetroWest Medical Center,
Framingham, MA, USA
seungwooklee94@gmail.com






#OHDSISocialShowcase This Week

Friday

OHDSI AI: Generative AI-powered Knowledge Translation of OHDSI Research Literature and Singapore's Cardiovascular Research

(**Maisie Ng**, Cindy Ho, Li Ting Ang, Hang Png, Shuen Lin Tan, Estella Ye, Ismail Mohd, Mengling Feng, Sebastian Maurer-Stroh, Johan G Eriksson, Mukkesh Kumar)





Where Are We Going?

**Any other announcements
of upcoming work, events,
deadlines, etc?**



Three Stages of The Journey

Where Have We Been?

Where Are We Now?

Where Are We Going?





April 22: Estimation and Prediction



George Hripcsak

Vivian Beaumont Allen Professor of Biomedical Informatics, Columbia University



Marc Suchard

Professor of Biostatistics, Biomathematics, & Human Genetics, UCLA



Ross Williams

Assistant Professor, Erasmus University Medical Centre



Egill Fridgeirsson

Scientific Researcher/Postdoc, Erasmus University Medical Centre



Jenna Reps

Associate Director, Observational Health Data Analytics, Johnson & Johnson



**The weekly OHDSI community call is held
every Tuesday at 11 am ET.**

Everybody is invited!

**Links are sent out weekly and available at:
ohdsi.org/community-calls-2025**